QuidelOrtho Corporation Investor Presentation — November 2022

Document content

Forging the Future of Diagnostics

Financial Results 3Q 2022

November 2, 2022 © QuidelOrtho 2022 2Forward -Looking Statements

Forward -Looking Statements: This presentation of QuidelOrtho Corporation (“QuidelOrtho” or the “Company”) contains “forward -looking statements” within the m eaning of the

Private Securities Litigation Reform Act of 1995. You can identify these statements and other forward -looking statements in this presentation by words such as “may,” “will,” “would,”

“expect,” “anticipate,” “believe,” “estimate,” “plan,” “intend,” “continue,” or similar words, expressions or the negative of such terms or other comparable terminology. These statements

include, but are not limited to, the benefits and results of the business combination by and among QuidelOrtho, Quidel Corpor ation (“Quidel”), Ortho Clinical Diagnostics Holdings plc

(“Ortho”) and certain other entities (the “Combinations”) and integration of the businesses of Quidel and Ortho, including Qu idelOrtho’s execution of cost and revenue synergies,

commercial, integration and other strategic goals, future financial and operating results, future plans, objectives, strategi es,expectations and intentions and other statements that are

not historical facts. Such statements are based on the beliefs and expectations of QuidelOrtho’s management as of today and a re subject to significant risks and uncertainties. Actual

results may differ significantly from those set forth or implied in the forward -looking statements. The following factors, among others, could cause actual results to differ from those set

forth or implied in the forward -looking statements: the challenges and costs of integrating, restructuring and achieving anticip ated synergies as a result of the Combinations; the ability